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Abstract
Genome-wide studies of transcription in the skeletal muscle of type 2 diabetic patients have
identified coordinated changes in the expression of genes involved in oxidative phosphorylation, and
have underlined the central role of the oxidative-phosphorylation regulator, PCG1. These findings
help unravel the complex pathogenesis and inheritance of polygenic type 2 diabetes mellitus.
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Type 2 diabetes mellitus is a heterogeneous clinical entity,
characterized by high blood sugar levels or hyperglycaemia,
arising from a deteriorated tissue response to the biological
effects of insulin (insulin resistance) [1] and impaired
glucose-induced insulin secretion [2]. It is a classical
example of multifactorial disorder: the etiology of type 2 dia-
betes combines both genetic and environmental factors. The
‘westernized lifestyle’ is a likely cause of the recent rapid rise
in disease incidence, which is projected to double worldwide
by the year 2025 (of 150 million diabetics globally, approxi-
mately 90% live in western countries). The management of
type 2 diabetes and its complications accounts for a signifi-
cant share of national annual healthcare spending in all
western countries. Together, these facts have galvanized
international efforts to research the causes of type 2 diabetes
mellitus and to develop effective preventive and therapeutic
tools and strategies for managing the disease.
Identifying causes and consequences of
hyperglycaemia
International genetic and genomic projects have delivered a
wide range of tools and resources for genome-wide investi-
gations to help the search for genetic factors involved in type 2
diabetes mellitus and have contributed to recent progress in
our knowledge of the etiology of the disease (for the remain-
der of this article, when we say ‘diabetes’ we mean type 2
diabetes mellitus). Genetic markers and dense genetic maps
allow extensive searches for gene variants that co-segregate
with the disease. Although many genetic loci have been
described that are linked to either diabetes or associated
pathophysiological markers [3], CALPAIN10 remains the only
known gene underlying polygenic type 2 diabetes mellitus [4].
The vast amount of information derived from the annotation
of the human genome and the genomes of model organisms
provide opportunities for using new strategies to identify
genes underlying diabetes. Knowledge of the human tran-
scriptome and proteome provides unparalleled power for
searching comprehensively for the causes and consequences
of the disease, and diagnostic and therapeutic targets and
agents relevant to it. In theory it is possible to characterize
gene-expression patterns (in terms of transcription, transla-
tion and post-translational changes) in any cell type and to
generate a broad functional picture of the molecular mecha-
nisms involved in health and disease. Differences in gene
expression between diabetic patients and controls are
indicative of a relationship between a specific gene or series
of genes and the disease in a specific context.
The transcriptome forms the crucial intermediate between
the genetic-code template and the protein products that con-
stitute the structural components and operational machin-
ery of organisms. The technology required to array large
numbers of transcripts or oligonucleotides and detect differ-
ences in the amount of individual transcripts is obviouslymore straightforward than that required for high-throughput
genome-wide protein screening. Fast and efficient genome-
wide transcription profiling, using microarrays, can reveal an
overall picture of genes potentially involved in the causes and
consequences of a disease, and this technology has been suc-
cessfully used in various fields of biomedical research. 
The diabetic muscle transcriptome
Skeletal muscle constitutes about 40% of mammalian body
mass and is, with fat and liver tissues, a key site of insulin
stimulated glucose disposal [5]. Impaired insulin-mediated
glucose disposal by muscle is a key feature of diabetes [6] and
skeletal muscles are, therefore, key tissue targets for gene-
expression studies of diabetes. Two recent landmark studies
[7,8] have used microarray analyses to highlight the central
role in the human diabetic-muscle phenotype of two key reg-
ulators of oxidative phosphorylation: the peroxisome prolif-
eration-activated receptor- (PPAR) coactivator 1 (PGC1)
and nuclear respiratory factor (NRF1). These studies were
based on determination of the expression levels of large sets
of 7,129 [8] and 22,000 genes [7], respectively, in muscle
biopsies of diabetic patients, prediabetics and controls.
Novel analytical methods used to exploit the microarray data
generated in the two studies clearly underline the impor-
tance of considering modest but coordinated changes in
genome-wide transcription patterns, rather than individual
changes that meet an arbitrary threshold. None of the genes
examined in either study was differentially expressed between
the different groups tested (diabetic patients, prediabetics
and controls) following robust statistical correction for false
discovery during multiple hypothesis testing. Both studies
examined differential covariation - between test subject
groups or classes - of sets of genes (within gene group
covariation). Genes were labeled by ontology classification,
then ranked by differential expression, and this sequential
procedure facilitated the detection of pathway-dependent
co-regulated genes. Mootha et al. [7] computed a Kolmogorov-
Smirnov test statistic (termed Gene Sets Enrichment
Approach, or GSEA) for each gene, which was then evalu-
ated against an empirically determined (permutation test)
threshold for declaring association between a gene set and
diabetes. In contrast, Patti et al. [8] examined only genes
that were differentially expressed before correction for
multiple testing (p < 0.05).
Remarkably, both studies found that the transcription levels
of a class of genes involved in oxidative phosphorylation
mechanisms were consistently lower in diabetics than in
controls, even following robust correction for multiple
testing, and both therefore suggested that the downregula-
tion of mitochondrial oxidative phosphorylation genes may
precede diabetes onset. The results of real-time quantitative
PCR demonstrated that the expression of NRF1, which regu-
lates the expression of nuclear-encoded mitochondrial
genes, was decreased by 29% in diabetics compared to non-
diabetics [8]. Both studies [7,8] also found that PGC1
expression was significantly lower (22-36%) in diabetics
than in other test groups, and Patti et al. [8] showed that
PGC1 expression was also significantly decreased (46%) in
diabetics compared to non-diabetic subjects. 
Importance of genetic and genomic expression
studies 
Poor replicability of significant genetic linkage and associa-
tion to a disease is often attributed to a number of factors,
including, for example, ethnic stratification, population-
specific linkage disequilibrium between markers and causal
variants, and gene-by-gene and gene-by-environment inter-
actions. The possible importance of some of these factors has
been addressed in an attempt to replicate previously pub-
lished associations in 16 candidate genes for type 2 diabetes
mellitus. The gene encoding PPAR was the only one for
which the study could confirm an association between
common variants and a significant increase in diabetes risk
[9]. The existence in a non-diabetic population of disease
susceptibility gene variants that are not expressed phenotyp-
ically, for example because of the late onset of diabetes, is
also a factor that reduces the power of genetic-linkage and
association analyses for this disease. Remarkably, although
Mootha et al. [7] and Patti et al. [8] independently investi-
gated patient samples from different populations (Mexican-
Americans and Caucasians, respectively) using different
microarrays and different data-analysis tools, the results
from both studies converged at the same gene pathway.
Using biological samples from patients selected for
homogenous clinical phenotypes may have minimized the
effect of genetic variability on gene transcription. It was,
however, reported that reduced oxidative phosphorylation
gene transcription was also found in ‘prediabetics’ [8]. 
Population size is also a key factor affecting the detection of
genetic linkage and association. Results from association
studies in type 1 diabetes mellitus provided support for the
requirement of very large population and family datasets to
improve the statistical robustness and reliability of genetic-
association studies of complex traits [10]. On the other hand,
screening a very large number of single nucleotide polymor-
phisms (SNPs) in a relatively modest panel of patients was
sufficient to identify a functional sequence variant associ-
ated with susceptibility to myocardial infarction [11]. It is
becoming apparent that, in contrast to traditional genetic
association studies, gene-expression profiling studies can
provide robust and functionally valid results with samples
from a very limited number of well-selected patients and
controls [7,8].
But in contrast to gene-expression profiling, genetic-linkage
mapping provides statistical evidence for the involvement of
chromosomal regions co-segregating with a disease or
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define etiologically important factors underlying multifactorial
disorders, in which potential biases are either minimized or
well defined. Unless all pathophysiological variables associated
with diabetes - glucose intolerance, altered insulin secretion
and action, obesity, dyslipidemia and high blood pressure - and
its complications are comprehensively characterized in both
patients and controls of a large cohort, results from linkage
analysis can only identify chromosomal regions involved in the
control of one phenotype. This strategy removes a number of
the constraints and limitations of functional studies, including
for example tissue- and developmental-stage-specific gene
expression. Most importantly, linkage analysis can point to
sequence elements, including pseudogenes [12], non
polyadenylated RNAs and non-coding sequences [13] that
may play an important unrecognized role in complex dis-
eases but cannot be directly tested by current microarray-
based transcription-profiling technologies.
Altered gene expression in diabetes - cause or
consequence?
Determining the causes and consequences of a complex
disease is the most challenging issue that genetic and func-
tional genomic studies currently attempt to address [14]. It
is pertinent to consider conceptually how decreased oxida-
tive phosphorylation might result in diabetes. A large body
of existing scientific literature supports the hypothesis of
Patti et al. [8]: decreased expression of PGC1 coupled with
reduced expression of NRF1 and PPAR eventually result in
decreased oxidative phosphorylation and lipid oxidation,
accumulation of lipid in skeletal muscle and ultimately dia-
betes. Many organs, including endocrine pancreas, liver and
fat, are important in maintaining glucose homeostasis and
energy balance. One must therefore consider whether differ-
ential transcription of components of the oxidative-phospho-
rylation pathway in diabetes is limited to muscle and how it
relates to the whole-organism functional picture of diabetes.
For example, ATP generated from oxidative phosphorylation
is required for normal glucose-stimulated insulin release. The
downregulation of oxidative-phosphorylation genes seen in
diabetic muscle would be expected to be mirrored in pancre-
atic islets and may account for a lack of insulin related to
beta-cell dysfunction in advanced diabetes [15]. 
In conclusion, transcriptomics is well advanced for techno-
logical reasons and will deliver vast amounts of information
on the complex regulation of tissue- and time-specific gene
expression in disease onset and progression. One of the
important perspectives of genome-wide transcriptomic
studies lies in the possibility to integrate genes and
expressed sequence tags (ESTs) of unknown or poorly
defined roles into functional pathways, thus improving func-
tional genome annotation. Although GSEA is a significant
advance for interpreting microarray data, it relies on our
current understanding of the regulation of metabolic and
hormonal networks. Results from the investigation of the
diabetic muscle transcriptome [7,8] suggest that gene-tran-
scription profiling on its own may have a limited impact on the
enrichment of system biology maps. Gene transcription,
however, represents only a single dimension in functional
genome maps. In particular, as exemplified by Epstein et al.
[16], post-translational modification is a crucial mechanism
for gene regulation that is not necessarily discernible by study-
ing the transcriptome. Metabonomics and metabolomics are
also genome-wide technologies that will enrich genome
annotation in health and disease [17,18]. Global integrative
analyses of multidimensional genomic parameters exploit-
ing the concept of a biological atlas advanced by Vidal et al.
[19] probably represents the most optimal use of resources
to isolate variables that are relevant to complex diseases in
the whole organism, and to describe their interplay.
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